Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 149–154

doi: 10.17219/acem/61428

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Campylobacter concisus as the etiologic agent of gastrointestinal diseases

Katarzyna Akutko1,A,D, Krzysztof Matusiewicz1,D,F

1 2nd Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland

Abstract

A number of reports on the pathogenic influence of Campylobacter concisus on the human body and its role in many diseases of the gastrointestinal system, including gastroesophageal reflux disease, Barrett’s esophagus and inflammatory bowel disease, have appeared lately. Campylobacter concisus is a Gram negative bacteria which requires an anaerobic environment or microaerophilic environment with hydrogen for growth and is therefore difficult to culture. Due to this difficulty, the rate of infections in epidemiological data are underestimated. There are reports that C. concisus was the only pathogen isolated from the stool of patients with acute diarrhea, which could indicate that it is an etiologic factor of acute gastrointestinal infections in humans. Moreover, the results of some studies suggest that infection with C. concisus is a factor predisposing to the development of gastroesophageal reflux disease and Barrett’s esophagus, conditions which may be present before the development of cancer. There are also studies which indicate C. concisus infection as a trigger of inflammatory bowel disease, since it has been demonstrated that C. concisus is present more frequently in patients with newly diagnosed Crohn’s disease than in a control group.

Key words

inflammatory bowel disease, Campylobacter concisus, reflux esophagitis, Barrett’s esophagus

References (35)

  1. Silva J, Leite D, Fernandes M, Mena C, Gibbs PA, Teixeira P. Campylobacter spp. as a Foodborne Pathogen: A Review. Front Microbiol. 2011;2:200. doi:10.3389/fmicb.2011.00200.x.
  2. Laroche M, Magras C. Gastrointestinal campylobacteriosis in industrialised countries: Comparison of the disease situation with salmonello-sis, and microbiological contamination assessment. Rev Sci Tech. 2013;32(3):701–­714.
  3. Fernández H, Vera F, Villanueva MP, García A. Occurrence of Campylobacter species in healthy well-nourished and malnourished children. Braz J Microbiol. 2008;39(1):56–58.
  4. Man SM. The clinical importance of emerging Campylobacter species. Nat Rev Gastroenterol Hepatol. 2011;8(12):669–685.
  5. Istivan T, Ward P, Coloe P. Campylobacter concisus: An emerging pathogen of the gastrointestinal tract. Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology. 2010; 626–634.
  6. Kaakoush NO, Mitchell HM. Campylobacter concisus – A new player in intestinal disease. Front Cell Infect Microbiol. 2012;2:4. doi:10.3389/fcimb.2012.00004.x.
  7. Zhang L, Lee H, Grimm MC, Riordan SM, Day AS, Lemberg DA. Campylobacter concisus and inflammatory bowel disease. World J Gastroenterol. 2014;20(5):1259–1267.
  8. Ismail Y, Mahendran V, Octavia S, et al. Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS ONE. 2012;7(5):e38217. doi:10.1371/journal.pone.0038217.x.
  9. Lastovica AJ. Emerging Campylobacter spp.: The tip of the iceberg. Clinical Microbiology Newsletter. 28(7):49–56.
  10. Nielsen HL, Ejlertsen T, Engberg J, Nielsen H. High incidence of Campylobacter concisus in gastroenteritis in North Jutland, Denmark: A population-based study. Clin Microbiol Infect. 2013;19(5):445–450.
  11. Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn’s disease. Inflamm Bowel Dis. 2010;16(6):1008–1016.
  12. Macfarlane S, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patients with Barrett’s esopha-gus. Clin Infect Dis. 2007;45(1):29–38.
  13. Man SM, Kaakoush NO, Leach ST, et al. Host attachment, invasion, and stimulation of proinflammatory cytokines by Campylobacter concisus and other non-Campylobacter jejuni Campylobacter species. J Infect Dis. 2010;202(12):1855–1865.
  14. Istivan TS, Smith SC, Fry BN, Coloe PJ. Characterization of Campylobacter concisus hemolysins. FEMS Immunol Med Microbiol. 2008; 54(2):224–235.
  15. Kaakoush NO, Deshpande NP, Wilkins MR, et al. The pathogenic potential of Campylobacter concisus strains associated with chronic intesti-nal diseases. PLoS ONE. 2011;6(12):e29045. doi:10.1371/journal.pone.0029045.
  16. Kaakoush NO, Man SM, Lamb S, et al. The secretome of Campylobacter concisus. FEBS J. 2010;277(7):1606–1617. doi: 10.1111/j.1742-4658.2010.07587.x.
  17. Stachowiak R, Bielecki J. Hemolizyny bakteryjne. Post Mikrobiol. 2000;39:253–270.
  18. Nielsen HL, Nielsen H, Ejlertsen T, et al. Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/B6 intestinal epithelial cells. PLoS ONE. 2011;6(8):e23858. doi:10.1371/journal.pone.0023858.x.
  19. Aabenhus R, On SL, Siemer BL, Permin H, Andersen LP. Delineation of Campylobacter concisus genomospecies by amplified fragment length polymorphism analysis and correlation of results with clinical data. J Clin Microbiol. 2005;43(10):5091–5096.
  20. Deshpande NP, Kaakoush NO, Mitchell H, et al. Sequencing and validation of the genome of a Campylobacter concisus reveals intra-species diversity. PLoS ONE. 2011;6(7):e22170. doi:10.1371/journal.pone.0022170.x.
  21. Hess DL, Pettersson AM, Rijnsburger MC, Herbrink P, van den Berg HP, Ang CW. Gastroenteritis caused by Campylobacter concisus. J Med Microbiol. 2012;61(5):746–749.
  22. Blackett KL, Siddhi SS, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: Association or causality? Aliment Pharmacol Ther. 2013;37(11):1084–1092.
  23. Zhang L, Man SM, Day AS, et al. Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn’s disease. J Clin Microbiol. 2009;47(2):453–455.
  24. Taubman MA, Haffajee AD, Socransky SS, Smith DJ, Ebersole JL. Longitudinal monitoring of humoral antibody in subjects with destructive periodontal diseases. J Periodontal Res. 1992;27(5):511–521.
  25. Henne K, Fuchs F, Kruth S, Horz HP, Conrads G. Shifts in Campylobacter species abundance may reflect general microbial community shifts in periodontitis progression. J Oral Microbiol. 2014;6. doi:10.3402/jom.v6.25874.x.
  26. Yang L, Francois F, Pei Z. Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012;18(8):2138–2144.
  27. Pei Z, Yang L, Peek RM, Jr Levine SM, Pride DT, Blaser MJ. Bacterial biota in reflux esophagitis and Barrett’s esophagus. World J Gastroenterol. 2005;11(46):7277–7283.
  28. Yang L, Oberdorf WE, Gerz E, et al. Foregut microbiome in development of esophageal adenocarcinoma. Nature Precedings. 2010. doi:10.1038/npre.2010.5026.1.x.
  29. Suerbaum S. Microbiome analysis in the esophagus. Gastroenterology. 2009;137(2):419–421.
  30. Tack J, Carethers JM. Different microbiome patterns in normal, inflammed, and Berrett’s esophagus. Gastroenterology. 2009;137(2):398–399.
  31. Peng DF, Hu TL, Soutto M, Belkhiri A, El-Rifai W. Glutathione peroxidase 7 suppresses bile salt-induced expression of pro-inflammatory cyto-kines in Barrett’s carcinogenesis. J Cancer. 2014;5(7):510–517.
  32. Zheng J, Meng J, Zhao S, Singh R, Song W. Campylobacter-induced interleukin-8 secretion in polarized human intestinal epithelial cells requires Campylobacter-secreted cytolethal distending toxin- and Toll-like receptor-mediated activation of NF-kappaB. Infect Immun. 2008;76(10):4498–4508.
  33. Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137(2):495–501.
  34. Shim JO. Gut microbiota in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16(1):17–21.
  35. Mukhopadhya I, Thomson JM, Hansen R, Berry SH, El-Omar EM, Hold GL. Detection of Campylobacter concisus and other Campylobacter species in colonic biopsies from adults with ulcerative colitis. PLoS ONE. 2011;6(6):e21490. doi:10.1371/journal.pone.0021490.